Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 19/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4140875 | 0.99 | P2RX7 (0.74) | P2RX7 | |
| SCHEMBL4121902 | 0.98 | P2RX7 (0.73) | P2RX7 | |
| SCHEMBL4141255 | 0.90 | P2RX7 (0.77) | P2RX7 | |
| SCHEMBL4122056 | 0.89 | P2RX7 (0.92) | P2RX7 | |
| SCHEMBL4141588 | 0.88 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL4122062 | 0.88 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL7085419 | 0.87 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL14402966 | 0.87 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL14347720 | 0.87 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL4122197 | 0.87 | P2RX7 (0.64) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | claimed |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | claimed |
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | claimed |
| EP-1352896-B1 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | claimed |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | claimed |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| US-20060247257-A1 | Combination | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | claimed |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale (FR) | 2020-02-04 | — | — | US | disclosed |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2019-01-24 | — | — | US | disclosed |
| US-20130195919-A1 | INDUCED DENDRITIC CELL COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013036299-A1 | TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036297-A1 | THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036293-A1 | DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2004105798-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| EP-1242364-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1352897-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352895-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | P2RX7, P2RY1, P2RX5 | P2RX7 1/4885 |
| US-20030013704-A1 | Adamantane derivatives | ADRA2C, CHRNA2, ADRA1D | P2RX7 1500/4885 |
| US-20090176853-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | P2RX7 1692/4885 |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885 |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885 |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | P2RX7, P2RX3, P2RX5 | P2RX7 1/4885 |
| US-20060247257-A1 | Combination | P2RX7, PCSK9, P2RX1 | P2RX7 1/4885 |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | P2RY1, P2RX3, P2RX7 | P2RX7 3/4885 |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885 |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.